| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $12,908,431 | 28 | 100 |
| Balice-Gordon Rita J. | director | 0 | $0 | 1 | $171,673 | $-171,673 |
| SANTINI GINO | director | 0 | $0 | 1 | $201,018 | $-201,018 |
| Freund John Gordon | director | 0 | $0 | 2 | $602,790 | $-602,790 |
| Smith Thomas B | EVP and Chief Medical Officer | 0 | $0 | 1 | $671,576 | $-671,576 |
| Rubric Capital Management LP | 10 percent owner | 0 | $0 | 1 | $946,250 | $-946,250 |
| Fallon John A. | director | 0 | $0 | 1 | $1.65M | $-1.65M |
| Tupper Colleen | EVP & Chief Financial Officer | 0 | $0 | 7 | $1.89M | $-1.89M |
| Kuhlmann Shirley R. | EVP and General Counsel | 0 | $0 | 4 | $3.34M | $-3.34M |
| Dreyer Scott | EVP & Chief Commercial Officer | 0 | $0 | 10 | $3.44M | $-3.44M |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Over the last 12 months, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $12.91M worth of Collegium Pharmaceutical, Inc. stock.
On average, over the past 5 years, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $9.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $183,600 was made by Brannelly Paul (Executive Vice President & CFO) on 2017‑05‑12.
| 2025-12-08 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 17,600 0.056% | $48.17 | $847,855 | +1.45% | |
| 2025-12-05 | Sale | Balice-Gordon Rita J. | director | 3,650 0.0113% | $47.03 | $171,673 | +2.88% | |
| 2025-11-12 | Sale | Fallon John A. | director | 34,853 0.1231% | $47.21 | $1.65M | +2.67% | |
| 2025-11-06 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 30,000 0.1072% | $40.53 | $1.22M | +14.22% | |
| 2025-08-29 | Sale | Smith Thomas B | EVP and Chief Medical Officer | 17,478 0.0549% | $38.42 | $671,576 | -6.80% | |
| 2025-08-18 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 16,389 0.052% | $38.21 | $626,171 | -0.86% | |
| 2025-08-15 | Sale | SANTINI GINO | director | 5,405 0.0169% | $37.19 | $201,018 | +0.61% | |
| 2025-08-13 | Sale | Rubric Capital Management LP | 10 percent owner | 25,000 0.0793% | $37.85 | $946,250 | -0.29% | |
| 2025-08-13 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 4,861 0.0155% | $38.03 | $184,881 | -0.29% | |
| 2025-08-08 | Sale | Freund John Gordon | director | 11,659 0.0357% | $34.36 | $400,641 | +8.23% | |
| 2025-06-09 | Sale | Freund John Gordon | director | 6,601 0.0207% | $30.62 | $202,149 | +16.06% | |
| 2025-03-21 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 6,396 0.0203% | $30.03 | $192,069 | +7.77% | |
| 2025-03-21 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 18,881 0.0599% | $30.03 | $566,983 | +7.77% | |
| 2025-03-20 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 1,206 0.0038% | $30.00 | $36,181 | +8.12% | |
| 2025-03-20 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 1,927 0.0061% | $30.00 | $57,811 | +8.12% | |
| 2025-03-14 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 977 0.0032% | $30.00 | $29,313 | +9.20% | |
| 2025-03-14 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 2,255 0.0073% | $30.00 | $67,661 | +9.20% | |
| 2025-03-11 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 10,445 0.0332% | $30.01 | $313,413 | +6.95% | |
| 2025-03-11 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 15,387 0.0489% | $30.00 | $461,672 | +6.95% | |
| 2025-03-07 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 1,504 0.005% | $30.00 | $45,121 | +10.83% |
| Rubric Capital Management LP | 10 percent owner | 3132743 9.9103% | $152.6M | 0 | 1 | |
| Tupper Colleen | EVP & Chief Financial Officer | 126667 0.4007% | $6.17M | 0 | 10 | |
| Kuhlmann Shirley R. | EVP and General Counsel | 108137 0.3421% | $5.27M | 0 | 15 | |
| Dreyer Scott | EVP & Chief Commercial Officer | 103613 0.3278% | $5.05M | 0 | 25 | |
| SANTINI GINO | director | 95042 0.3007% | $4.63M | 0 | 1 | |
| Smith Thomas B | EVP and Chief Medical Officer | 70264 0.2223% | $3.42M | 0 | 3 | |
| Fallon John A. | director | 64634 0.2045% | $3.15M | 1 | 1 | +26.87% |
| Balice-Gordon Rita J. | director | 52629 0.1665% | $2.56M | 0 | 1 | |
| Freund John Gordon | director | 23129 0.0732% | $1.13M | 1 | 2 | +44.38% |
| Skyline Venture Partners V LP | 10 percent owner | 2949916 9.3319% | $143.69M | 1 | 0 | +44.38% |
| Heron Patrick J | 1887332 5.9705% | $91.93M | 1 | 0 | +44.38% | |
| Frazier Healthcare VI, L.P. | 10 percent owner | 1887332 5.9705% | $91.93M | 1 | 0 | +44.38% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1325253 4.1924% | $64.55M | 1 | 0 | +44.38% | |
| Ciaffoni Joseph | President and CEO | 275000 0.87% | $13.4M | 0 | 31 | |
| Fleming Alison B | Chief Technical Officer | 148753 0.4706% | $7.25M | 0 | 12 | |
| Brannelly Paul | Executive Vice President & CFO | 123436 0.3905% | $6.01M | 1 | 1 | +42.57% |
| Longitude Capital Partners, LLC | 10 percent owner | 45620 0.1443% | $2.22M | 1 | 1 | +44.38% |
| BOHLIN GAREN G | director | 44775 0.1416% | $2.18M | 0 | 1 | |
| Heffernan Michael Thomas | director | 28023 0.0886% | $1.37M | 0 | 25 | |
| Hirsch David | director | 17117 0.0541% | $833,769.07 | 1 | 3 | +44.38% |
$910,099,463 | 123 | 11.52% | $2.57B | |
$12,831,842 | 73 | 20.01% | $2.07B | |
$218,350,131 | 64 | 16.68% | $732.84M | |
$14,599,168 | 59 | 12.79% | $1.82B | |
$129,489,279 | 57 | 26.09% | $656.14M | |
$102,709,455 | 46 | 30.55% | $1.19B | |
$11,542,910 | 40 | 56.19% | $1.66B | |
$73,312,053 | 38 | -4.37% | $1.79B | |
$21,068,600 | 35 | 9.64% | $1.27B | |
$6,021,989 | 30 | -0.17% | $577.96M | |
$12,998,723 | 30 | 3.46% | $3.83B | |
$6,506,230 | 27 | -16.20% | $1.21B | |
$83,406,412 | 19 | 21.96% | $2.7B | |
$1,843,996 | 10 | 22.92% | $1.18B | |
$1,718,514 | 9 | 38.12% | $1.56B | |
Collegium Pharmaceutical, Inc. (COLL) | $26,633,903 | 9 | 42.23% | $1.54B |
$179,515 | 7 | 1.51% | $659.04M | |
$614,633 | 6 | 27.88% | $1.64B | |
$543,932 | 6 | -22.02% | $695.69M |
| Increased Positions | 133 | +51.55% | 5M | +12.69% |
| Decreased Positions | 114 | -44.19% | 4M | -9.73% |
| New Positions | 44 | New | 1M | New |
| Sold Out Positions | 26 | Sold Out | 887,616 | Sold Out |
| Total Postitions | 277 | +7.36% | 37M | +2.95% |
| Blackrock, Inc. | $251,808.00 | 16.18% | 5.18M | -163,812 | -3.07% | 2025-09-30 |
| Rubric Capital Management Lp | $137,453.00 | 8.83% | 2.83M | -331,245 | -10.49% | 2025-09-30 |
| Eventide Asset Management, Llc | $116,270.00 | 7.47% | 2.39M | -250,489 | -9.48% | 2025-09-30 |
| Vanguard Group Inc | $108,269.00 | 6.96% | 2.23M | -21,833 | -0.97% | 2025-09-30 |
| Renaissance Technologies Llc | $77,769.00 | 5% | 1.6M | +78,019 | +5.13% | 2025-09-30 |
| Fuller & Thaler Asset Management, Inc. | $73,075.00 | 4.7% | 1.5M | +71,645 | +5.01% | 2025-09-30 |
| Principal Financial Group Inc | $63,694.00 | 4.09% | 1.31M | -157,104 | -10.71% | 2025-09-30 |
| State Street Corp | $62,923.00 | 4.04% | 1.29M | -60,506 | -4.47% | 2025-09-30 |
| Invesco Ltd. | $62,391.00 | 4.01% | 1.28M | -301,900 | -19.05% | 2025-09-30 |
| Janus Henderson Group Plc | $44,265.00 | 2.85% | 910,241 | +440,692 | +93.85% | 2025-09-30 |